Education
About Us
Working with TipRanks
Follow Us
ClearPoint Neuro (CLPT)
NASDAQ:CLPT
Top Page
ClearPoint Neuro
(NASDAQ:CLPT)
62Neutral
Positive Factors
Growth
Functional Neuro growth in Q4 was strong at 43% year-over-year.
Market Position
ClearPoint has established itself as the go-to provider for neurosurgery guidance – regardless of the operating location.
Negative Factors
Revenue Timing
The partner business recently had significant developments that accelerate $100s of millions of revenue opportunities, with 70%+ GMs, to being on the market as early as late 2026.
ClearPoint Neuro (CLPT) vs. S&P 500 (SPY)
Market Cap
$328.55M
Dividend YieldN/A
Average Volume (3M)274.19K
Price to Earnings (P/E)―
Beta (1Y)1.86
Revenue Growth31.04%
EPS Growth22.18%
CountryUS
Employees115
SectorHealthcare
Sector Strength65
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.70
Shares Outstanding27,632,332
10 Day Avg. Volume208,125
30 Day Avg. Volume274,187
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.78
Price to Cash Flow (P/CF)-71.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$25.00Price Target Upside90.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
ClearPoint Neuro Business Overview & Revenue Model
Company DescriptionClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
How the Company Makes MoneyClearPoint Neuro primarily generates revenue through the sale and leasing of its ClearPoint Neuro Navigation System, as well as disposable products associated with its use during surgical procedures. The company also earns income from service agreements and maintenance contracts related to their systems. Significant revenue streams include direct sales to hospitals and healthcare facilities, as well as partnerships and collaborations with medical device manufacturers and pharmaceutical companies that utilize ClearPoint's technology for drug delivery and other neurological applications. These partnerships often involve licensing agreements, which can provide additional revenue channels through royalties and milestone payments.
ClearPoint Neuro Financial Statement Overview
Summary
ClearPoint Neuro has demonstrated strong revenue growth and a solid balance sheet with low leverage. However, the company continues to face profitability challenges with a negative net profit margin and negative operating cash flow.Income Statement
ClearPoint Neuro has shown a consistent increase in revenue over the years, with a notable revenue growth rate of 31% from 2023 to 2024. However, the company continues to operate at a loss with a negative net profit margin of -60.3% in 2024. The gross profit margin remains strong at 60.9%, indicating efficient cost management relative to revenue. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.65
Positive
Balance Sheet
The company's balance sheet shows improvement in stockholders' equity, which increased to $25.4 million in 2024 from $21.2 million in 2023. The debt-to-equity ratio has improved significantly over the years, standing at 0.14 in 2024, indicating lower leverage risk. The equity ratio is robust at 64.8%, highlighting a strong capital structure. However, the company needs to address its negative net income for better return on equity.70
Positive
Cash Flow
ClearPoint Neuro's cash flow situation shows a positive trend in free cash flow growth, with free cash flow improving by 37.6% from 2023 to 2024. However, the operating cash flow remains negative, which could impact long-term sustainability. The company has been financing its operations through external funding, as seen in its financing cash flow.60
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 31.39M | 23.95M | 20.55M | 16.30M | 12.83M | Gross Profit |
| 19.12M | 13.61M | 13.53M | 11.29M | 9.12M | EBIT |
| -19.75M | -22.45M | -16.33M | -13.37M | -6.22M | EBITDA |
| -19.75M | -20.99M | -15.58M | -12.74M | -4.79M | Net Income Common Stockholders |
| -18.91M | -22.09M | -16.54M | -15.32M | -9.11M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 20.10M | 23.14M | 37.49M | 54.11M | 20.10M | Total Assets |
| 39.19M | 42.66M | 55.49M | 65.58M | 29.64M | Total Debt |
| 3.57M | 13.94M | 11.99M | 12.28M | 24.24M | Net Debt |
| -16.54M | -9.20M | -15.63M | -41.83M | 4.14M | Total Liabilities |
| 13.80M | 21.49M | 18.60M | 16.79M | 27.26M | Stockholders Equity |
| 25.39M | 21.17M | 36.89M | 48.79M | 2.38M |
| Cash Flow | Free Cash Flow | |||
| -9.22M | -14.77M | -17.31M | -12.87M | -8.29M | Operating Cash Flow |
| -8.95M | -13.72M | -16.17M | -12.70M | -7.81M | Investing Cash Flow |
| -275.00K | 8.95M | -10.74M | -168.00K | -482.00K | Financing Cash Flow |
| 6.19M | 296.00K | 409.00K | 46.88M | 22.69M |
ClearPoint Neuro Technical Analysis
Neutral
13.09
Price Trends
15.57
Negative
14.70
Negative
12.24
Positive
Market Momentum
-0.77
Negative
45.45
Neutral
32.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLPT, the sentiment is Neutral. The current price of 13.09 is above the 20-day moving average (MA) of 13.00, below the 50-day MA of 15.57, and above the 200-day MA of 12.24, indicating a neutral trend. The MACD of -0.77 indicates Negative momentum. The RSI at 45.45 is Neutral, neither overbought nor oversold. The STOCH value of 32.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLPT.
ClearPoint Neuro Risk Analysis
ClearPoint Neuro disclosed 49 risk factors in its most recent earnings report. ClearPoint Neuro reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ClearPoint Neuro Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $328.55M | ― | -81.24% | ― | 31.04% | 22.18% | |
59 Neutral | $151.32M | ― | -144.19% | ― | 0.55% | -8.47% | |
50 Neutral | $9.11M | ― | -45.38% | ― | -48.61% | 32.18% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
43 Neutral | $1.96B | ― | -46.67% | ― | 18.82% | 19.76% | |
30 Underperform | $57.85M | ― | 78.44% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
CLPT
ClearPoint Neuro
13.09
6.49
98.33%
LUNA
Luna Innovations
0.56
-2.47
-81.52%
NURO
Neurometrix
4.41
0.56
14.55%
STXS
Stereotaxis
1.75
-1.20
-40.68%
NVCR
NovoCure
17.52
3.10
21.50%
BYSI
Beyondspring
1.62
-1.60
-49.69%
ClearPoint Neuro Earnings Call Summary
Earnings Call Date: Feb 26, 2025 | % Change Since: -23.98% | Next Earnings Date: May 13, 2025
Earnings Call Sentiment Positive
ClearPoint Neuro demonstrated strong financial performance with significant revenue growth across various segments and improved gross margins. The company launched several new products and achieved a debt-free status, indicating positive strategic progress. However, there were challenges with a decrease in cash position and increased operating expenses, which slightly dampen the overall positive outlook.Highlights
Record Revenue Growth
ClearPoint Neuro reported total revenues of $31.4 million for the year ended December 31, 2024, representing a 31% increase over the previous year's revenue of $24 million.
Strong Biologics and Drug Delivery Growth
Biologics and drug delivery revenue increased by 27% to $17.3 million in 2024, driven by an increase in product sales as pharmaceutical partners advanced their development programs.
Capital Equipment and Software Surge
Capital equipment and software revenue grew 107% to $3.8 million for the year 2024, indicating significant expansion of the installed base.
Improved Gross Margin
Gross margin for the full year 2024 was 61%, up from 57% in 2023, primarily due to lower costs from transitioning to a new manufacturing facility and higher volumes.
Successful New Product Launches
Successfully launched new MR navigation systems, operating room navigation systems, drug delivery technologies, laser therapy and access products, and preclinical and clinical drug discovery services.
Debt-Free Status Achieved
Completed an equity offering with net proceeds of $16.2 million, allowing the company to retire all outstanding debt and end 2024 debt-free.
Lowlights
Cash Position Decrease
Cash and cash equivalents decreased to $20.1 million at the end of December 2024, from $23.1 million at the end of 2023, primarily due to operating cash needs.
Increased Operating Expenses
Operating expenses for the fourth quarter of 2024 increased to $10.4 million from $8.7 million in the same period of 2023, driven by increased headcount and share-based compensation.
Reduction in Service Revenue
In the fourth quarter of 2024, there was a 12% decrease in service revenue within the biologics and drug delivery segment.
Company Guidance
During the call, ClearPoint Neuro, Inc. provided guidance for 2025, emphasizing their transition into the "Fast. Forward" phase. The company anticipates total revenue for 2025 to be between $36 million and $41 million, representing a growth of 15% to 31% compared to 2024. In 2024, total revenues were $31.4 million, a 31% increase from $24 million in 2023. The revenue was split into biologics and drug delivery, neurosurgery navigation therapy, and capital equipment and software. Biologics and drug delivery revenue saw a 27% increase, while neurosurgery navigation revenue grew by 21%. Capital equipment and software revenue experienced a significant 107% increase. The company's gross margin improved to 61% from 57% in 2023. Research and development costs increased by 6%, and sales and marketing expenses rose by 15%, while general and administrative expenses saw a slight 2% increase. ClearPoint's operational cash burn decreased by 35%, with cash and cash equivalents standing at $20.1 million at the end of 2024. The company aims to extend its lead in cell and gene therapy delivery, evolve its product portfolio, and expand its global installed base, targeting the approval of additional therapies within the next two years.ClearPoint Neuro Corporate Events
Business Operations and StrategyFinancial Disclosures
ClearPoint Neuro Reports Record 2024 Revenue Growth
Positive
Feb 26, 2025
On February 26, 2025, ClearPoint Neuro announced its financial results for the fourth quarter and full year of 2024, highlighting a record revenue of $31.4 million for the year, marking a 31% increase over 2023. The company reduced its operational cash burn by 35% and activated 25 new global centers in 2024. ClearPoint Neuro aims to expand its global footprint and accelerate the launch of new products, focusing on supporting BioPharma partners in the commercialization of cell and gene therapies. The company anticipates revenue growth between 15% and 31% for 2025.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.